POLA2
POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Overview
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands.
Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.85, affected pathway 0.61, genetic association 0.06, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
- 1 · What it is
POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
- 2 · What goes wrong in cancer
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis.
- 3 · How drugs use it
No product in this corpus aims at POLA2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:30073 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14181 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000014138 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Biology
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. Location: Nucleus (UniProt). Locus 11q13.1 (HGNC).
- Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908)
- Lung cancer: Open Targets association 0.60 with lung cancer (MONDO_0008903)
- Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)
- Breast cancer: Open Targets association 0.58 with breast cancer (MONDO_0007254)
- Ovarian cancer: Open Targets association 0.58 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"POLA2" OR ABSTRACT:"POLA2" OR TITLE:"DNA polymerase alpha 2, accessory subunit" OR ABSTRACT:"DNA polymerase alpha 2, accessory subunit" OR TITLE:"DNA polymerase alpha subunit B" OR ABSTRACT:"DNA polymerase alpha subunit B" OR TITLE:"FLJ21662" OR ABSTRACT:"FLJ21662") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLA2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPOLD2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLE2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLE3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPRIM1
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPRIM2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetRRM2B
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).